Kineta’s dalazatide (formerly ShK-186) has a mechanism of action broad enough to treat many autoimmune diseases

April 14, 2015 /

MS Research Study and Reports

Grant Awards

Kineta’s Autoimmune Program is supported by the National Institute of Health.

DEVELOPMENT OF KV1.3 CHANNEL BLOCKER SHK-186 AS A THERAPY FOR MULTIPLE SCLEROSIS
1R43AI085691-01
PI: Shawn P. Iadonato

Listed as: Funding Mechanism, Title, Application #, Collaborators (if any)

Read more, here

~~~~~~~~~~~~~~~~~~~~

Keep CURRENT with MS Views and News – OPT-IN here

.
.

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews

Stay informed with MS news and information - Sign-up here

For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT